FES
MOLECULAR TARGETFES proto-oncogene, tyrosine kinase
FES (FES proto-oncogene, tyrosine kinase) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting FES
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | foretinib | 4.34 | 76 |
| 2 | tozasertib | 4.33 | 75 |
| 3 | ceritinib | 4.19 | 65 |
| 4 | bosutinib | 4.08 | 58 |
| 5 | bi 2536 | 4.01 | 54 |
| 6 | brigatinib | 3.81 | 44 |
| 7 | pazopanib | 3.69 | 39 |
| 8 | neratinib | 3.66 | 38 |
| 9 | nintedanib | 3.61 | 36 |
| 10 | pelitinib | 3.50 | 32 |
| 11 | tae 684 | 3.43 | 30 |
| 12 | fedratinib | 3.40 | 29 |
| 13 | rociletinib | 3.18 | 23 |
| 14 | lestaurtinib | 3.04 | 20 |
| 15 | danusertib | 2.94 | 18 |
| 16 | r 406 | 2.83 | 16 |
| 17 | hesperadin | 2.77 | 15 |
| 18 | plx 4720 | 2.71 | 14 |
| 19 | kw 2449 | 2.64 | 13 |
| 20 | ast 487 | 2.56 | 12 |
| 21 | lorlatinib | 2.48 | 11 |
| 22 | azd 7762 | 2.30 | 9 |
| 23 | bms 754807 | 2.30 | 9 |
| 24 | rebastinib | 2.20 | 8 |
| 25 | asp 3026 | 2.08 | 7 |
| 26 | amg 900 | 2.08 | 7 |
| 27 | pf 03814735 | 1.79 | 5 |
| 28 | ucn 01 | 1.79 | 5 |
| 29 | Crizotinib | 0.69 | 1 |
| 30 | Dasatinib | 0.69 | 1 |
| 31 | sp600125 | 0.69 | 1 |
About FES as a Drug Target
FES (FES proto-oncogene, tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented FES interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
FES inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.